In conclusion, small molecule-mediated G4 targeting may represent a promising therapeutic strategy for ALT-positive osteosarcoma and for other tumours that maintain telomeres via ALT (e.g., soft-tissue sarcomas) [13]. The gene discussed is GPT; the disease is soft tissue sarcoma.